Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asim Amin

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
International Journal of Cancer|September 26, 2006
Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patientsMuhammad U Rashid, Anbreen Zaidi, Diana Torres, et al.
Journal for Immunotherapy of Cancer|August 18, 2016
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanomaAsim Amin, David H Lawson, April K S Salama, et al.
Journal for Immunotherapy of Cancer|February 5, 2024
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)Margaret Callahan, Asim Amin, Frederic J Kaye, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 20, 2024
The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based ImmunotherapiesKirk D Beebe, Joel R Eisner, John Guo, et al.
Cancer Research Communications|March 16, 2023
Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal CancerJoel R Eisner, Kirk D Beebe, Gregory M Mayhew, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|February 5, 2021
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2Joseph I Clark, Brendan Curti, Elizabeth J Davis, et al.
Cancer Discovery|August 30, 2018
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudyAntoni Ribas, Theresa Medina, Shivaani Kummar, et al.
Journal for Immunotherapy of Cancer|October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer|March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyHans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
International Journal of Cancer|September 26, 2006
Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patientsMuhammad U Rashid, Anbreen Zaidi, Diana Torres, et al.
Journal for Immunotherapy of Cancer|August 18, 2016
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanomaAsim Amin, David H Lawson, April K S Salama, et al.
Journal for Immunotherapy of Cancer|February 5, 2024
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)Margaret Callahan, Asim Amin, Frederic J Kaye, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 20, 2024
The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based ImmunotherapiesKirk D Beebe, Joel R Eisner, John Guo, et al.
Cancer Research Communications|March 16, 2023
Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal CancerJoel R Eisner, Kirk D Beebe, Gregory M Mayhew, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|February 5, 2021
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2Joseph I Clark, Brendan Curti, Elizabeth J Davis, et al.
Cancer Discovery|August 30, 2018
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudyAntoni Ribas, Theresa Medina, Shivaani Kummar, et al.
Journal for Immunotherapy of Cancer|October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer|March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyHans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Pageof 6